[{"address1": "697 Burke Road", "address2": "Suite 201", "city": "Camberwell", "state": "VIC", "zip": "3124", "country": "Australia", "phone": "61 3 9092 0475", "fax": "61 3 8678 1269", "website": "https://www.tryptherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company's lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, currently under phase 2a clinical stager for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia, and irritable bowel syndrome. The company was founded in 2019 and is based in Camberwell, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Jason  Carroll", "title": "MD, CEO & Executive Director", "fiscalYear": 2024, "totalPay": 858548, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James P. Gilligan MSIB, Ph.D.", "age": 72, "title": "President & Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 299234, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William James Garner M.D., M.P.H., MPH", "age": 58, "title": "Founder & MD", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 39195, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Hamish  George B.Com., C.A.", "title": "Chief Financial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D.", "age": 76, "title": "Chief Medical Officer", "yearBorn": 1948, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David James Franks BEc, C.A., F Fin, J.P.", "age": 54, "title": "Company Secretary", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 4, "open": 0.0225, "dayLow": 0.0225, "dayHigh": 0.0225, "regularMarketOpen": 0.0225, "regularMarketDayLow": 0.0225, "regularMarketDayHigh": 0.0225, "volume": 90000, "regularMarketVolume": 90000, "averageVolume": 122883, "averageVolume10days": 32242, "averageDailyVolume10Day": 32242, "bid": 0.0112, "ask": 0.028, "marketCap": 30914102, "fiftyTwoWeekLow": 0.0007, "fiftyTwoWeekHigh": 0.0385, "priceToSalesTrailing12Months": 23.292004, "fiftyDayAverage": 0.020961, "twoHundredDayAverage": 0.014420213, "trailingAnnualDividendYield": "NaN", "currency": "USD", "enterpriseValue": 27207472, "floatShares": 676508223, "sharesOutstanding": 1276419968, "heldPercentInsiders": 0.25865, "heldPercentInstitutions": 0.00815, "impliedSharesOutstanding": 1577250048, "bookValue": 0.005, "priceToBook": 3.92, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1709164800, "netIncomeToCommon": -7371084, "trailingEps": -0.02, "lastSplitFactor": "1:2.5", "lastSplitDate": 1713139200, "enterpriseToRevenue": 20.499, "enterpriseToEbitda": -5.884, "52WeekChange": 2.92, "SandP52WeekChange": 0.23631513, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "TYPTF", "underlyingSymbol": "TYPTF", "firstTradeDateEpochUtc": 1720186200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "3d3198f6-312e-3e76-8b6c-fdb3a0460959", "messageBoardId": "finmb_693911067", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.0196, "recommendationKey": "none", "totalCash": 420806, "ebitda": -4624144, "totalDebt": 5305408, "quickRatio": 3.694, "currentRatio": 3.865, "totalRevenue": 1327241, "revenuePerShare": 0.003, "grossProfits": -1020004, "operatingCashflow": -7200070, "grossMargins": -0.76851, "operatingMargins": -3.4901502, "financialCurrency": "AUD", "trailingPegRatio": null, "__fetch_time": "2025-01-18"}]